Covered recipient · General Payments record
MICHELLE D WELCH
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$42,488.67
174 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $36,500.00 | 27 |
| Food and Beverage | $5,479.17 | 142 |
| Travel and Lodging | $485.27 | 3 |
| Education | $24.23 | 2 |
By paying entity
PY2025 · entire year · sorted by reported total
Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MICHELLE D WELCH
NPI 1891764957 · CMS profile ID 358563
Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
SHAVANO PARK, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1891764957?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MICHELLE D WELCH, NPI 1891764957, CMS profile ID 358563. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891764957?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). MICHELLE D WELCH, NPI 1891764957, CMS profile ID 358563. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891764957?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- MICHELLE D WELCH, NPI 1891764957, CMS profile ID 358563, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1891764957?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
174 matching records · $42,488.67 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 174.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Medtronic, Inc. | $151.29 | 08/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1219099490 | CMS |
| ABBVIE INC. | $10.71 | 08/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204721986 | CMS |
| Novo Nordisk Inc | $125.00 | 08/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188842713 | CMS |
| Amgen Inc. | $9.65 | 08/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1227234410 | CMS |
| SANOFI-AVENTIS U.S. LLC | $18.86 | 08/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233342025 | CMS |
| Lilly USA, LLC | $7.74 | 08/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186760217 | CMS |
| Tandem Diabetes Care, Inc. | $96.55 | 08/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1241304355 | CMS |
| Dexcom, Inc. | $100.69 | 08/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250509217 | CMS |
| Madrigal Pharmaceuticals | $34.63 | 08/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248321813 | CMS |
| Novo Nordisk Inc | $40.73 | 08/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188337093 | CMS |
| Echosens North America, Inc. | $99.23 | 07/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1243935194 | CMS |
| Sequel Med Tech, LLC | $147.94 | 07/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1243757543 | CMS |
| Madrigal Pharmaceuticals | $22.55 | 07/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248321811 | CMS |
| Amgen Inc. | $15.41 | 07/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228651329 | CMS |
| Amgen Inc. | $80.10 | 07/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228651337 | CMS |
| Novartis Pharmaceuticals Corporation | $17.40 | 07/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200388246 | CMS |
| Sequel Med Tech, LLC | $22.43 | 07/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1243757538 | CMS |
| Novo Nordisk Inc | $14.51 | 07/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1189107310 | CMS |
| Madrigal Pharmaceuticals | $57.83 | 07/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248321809 | CMS |
| ABBVIE INC. | $12.37 | 07/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204721981 | CMS |
| SANOFI-AVENTIS U.S. LLC | $17.99 | 07/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233342019 | CMS |
| Regeneron Healthcare Solutions, Inc. | $16.02 | 07/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213070008 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $107.89 | 07/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222995572 | CMS |
| Amgen Inc. | $1,800.00 | 07/04/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226924776 | CMS |
| Soleno Therapeutics, Inc. | $28.23 | 07/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1241819950 | CMS |
| Dexcom, Inc. | $22.49 | 07/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250509215 | CMS |
| Madrigal Pharmaceuticals | $96.54 | 06/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248321807 | CMS |
| Dexcom, Inc. | $150.99 | 06/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250509213 | CMS |
| Mannkind Corporation | $15.42 | 06/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250884966 | CMS |
| ABBVIE INC. | $9.33 | 06/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204721977 | CMS |
| SANOFI-AVENTIS U.S. LLC | $24.24 | 06/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233342189 | CMS |
| Tandem Diabetes Care, Inc. | $35.54 | 06/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1241304351 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.41 | 06/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214773875 | CMS |
| Sequel Med Tech, LLC | $13.46 | 06/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1243757530 | CMS |
| BETA BIONICS, INC. | $1.62 | 06/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246811522 | CMS |
| BETA BIONICS, INC. | $13.69 | 06/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246811540 | CMS |
| Novartis Pharmaceuticals Corporation | $14.42 | 06/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200388242 | CMS |
| Lilly USA, LLC | $900.00 | 05/30/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186761660 | CMS |
| KYOWA KIRIN, INC. | $16.85 | 05/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222109332 | CMS |
| Radius Health, Inc. | $71.66 | 05/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1249517967 | CMS |
| SANOFI-AVENTIS U.S. LLC | $15.22 | 05/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233342183 | CMS |
| Sequel Med Tech, LLC | $22.94 | 05/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1243757525 | CMS |
| Lilly USA, LLC | $900.00 | 05/15/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186832734 | CMS |
| ABBVIE INC. | $13.55 | 05/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204721973 | CMS |
| SANOFI-AVENTIS U.S. LLC | $28.69 | 05/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233342177 | CMS |
| Lilly USA, LLC | $900.00 | 05/13/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186806087 | CMS |
| BETA BIONICS, INC. | $41.81 | 05/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246810069 | CMS |
| Lilly USA, LLC | $900.00 | 05/09/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186812993 | CMS |
| Insulet Corporation | $15.94 | 05/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207085230 | CMS |
| Dexcom, Inc. | $71.61 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250509211 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $3,768,634.20 | 449 |
| PY2024 | Recipient | $105,211.00 | 8 |
| PY2024 | Principal investigator | $2,664,060.78 | 826 |
| PY2023 | Recipient | $7,665.94 | 7 |
| PY2023 | Principal investigator | $2,566,952.03 | 465 |
| PY2022 | Recipient | $76,525.00 | 9 |
| PY2022 | Principal investigator | $1,989,989.08 | 364 |
| PY2021 | Recipient | $7,260.42 | 3 |
| PY2021 | Principal investigator | $2,662,897.61 | 571 |
| PY2020 | Recipient | $17,198.80 | 12 |
| PY2020 | Principal investigator | $1,760,442.61 | 143 |
| PY2019 | Recipient | $8,139.00 | 2 |
| PY2019 | Principal investigator | $1,428,906.85 | 208 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
449 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $5,520.00 | 12/31/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism | No dispute reported | 06/30/2026 | 1202533825 |
| Principal investigator 1 | Eli Lilly and Company | $8,268.00 | 12/30/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES (SYNERGY-OUTCOMES); N1T-MC-TZ01; N1T-MC-RT01 | No dispute reported | 06/30/2026 | 1187880255 |
| Principal investigator 1 | PFIZER INC. | $1,227.94 | 12/24/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE | No dispute reported | 06/30/2026 | 1228746733 |
| Principal investigator 1 | Eli Lilly and Company | $4,792.00 | 12/23/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A PHASE 2, RANDOMIZED, OPEN-LABEL, COMPARATOR-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3938577 IN STUDY PARTICIPANTS, WITH TYPE 2 DIABETES MELLITUS PREVIOUSLY TREATED WITH BASAL INSULIN | No dispute reported | 06/30/2026 | 1187881414 |
| Principal investigator 1 | Novo Nordisk AS | $209.82 | 12/22/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN8640-4515 | No dispute reported | 06/30/2026 | 1213703437 |
| Principal investigator 1 | Novo Nordisk AS | $1,540.13 | 12/22/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4352 | No dispute reported | 06/30/2026 | 1213729689 |
| Principal investigator 1 | Novo Nordisk AS | $1,104.19 | 12/22/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4352 | No dispute reported | 06/30/2026 | 1213758565 |
| Principal investigator 1 | Genentech, Inc. | $4,889.00 | 12/19/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211590585 |
| Principal investigator 1 | Genentech, Inc. | $2,561.00 | 12/19/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590589 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,152.00 | 12/19/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211590630 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 12/18/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220995144 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 12/17/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647301 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 12/17/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647303 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.44 | 12/17/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647305 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.42 | 12/17/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647307 |
| Principal investigator 1 | Eli Lilly and Company | $915.38 | 12/17/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES | No dispute reported | 06/30/2026 | 1187878743 |
| Principal investigator 1 | Eli Lilly and Company | $1,395.66 | 12/17/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES | No dispute reported | 06/30/2026 | 1187880047 |
| Principal investigator 1 | Eli Lilly and Company | $28,189.00 | 12/15/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT REDUCTION WITH MACUPATIDE AND ELORALINTIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187881412 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22,386.60 | 12/10/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220819025 |
| Principal investigator 1 | ABBVIE INC. | $2,306.56 | 12/05/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202529258 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 12/04/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590561 |
| Principal investigator 1 | Genentech, Inc. | $10,964.00 | 12/04/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590565 |
| Principal investigator 1 | Genentech, Inc. | $1,492.00 | 12/04/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590569 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 12/04/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590572 |
| Principal investigator 1 | Genentech, Inc. | $8,500.00 | 12/04/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590576 |
| Principal investigator 1 | Genentech, Inc. | $205.00 | 12/04/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590580 |
| Principal investigator 1 | Genentech, Inc. | $3,000.00 | 12/04/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590592 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,278.00 | 12/04/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211590634 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $363.55 | 12/04/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184269199 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647289 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647291 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647293 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647295 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647297 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647299 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647479 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647481 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647483 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220647499 |
| Principal investigator 1 | Genentech, Inc. | $7,676.00 | 11/25/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211590549 |
| Principal investigator 1 | Genentech, Inc. | $3,925.00 | 11/20/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211590545 |
| Principal investigator 1 | Genentech, Inc. | $746.00 | 11/20/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590557 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,233.00 | 11/20/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211590626 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,975.78 | 11/20/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263663 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 11/19/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647485 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 11/19/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647487 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.96 | 11/19/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647489 |
| Principal investigator 1 | Genentech, Inc. | $2,698.00 | 11/14/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590541 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $8,616.00 | 11/14/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211590621 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,061.93 | 11/14/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184261327 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,862.60 | 11/13/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220819041 |
| Principal investigator 1 | Amgen Inc. | $6,493.04 | 11/10/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH, LLC | A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects With Moderate-to-Severe Active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1246640507 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,248.68 | 11/07/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258967 |
| Principal investigator 1 | PFIZER INC. | $96.00 | 11/06/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE | No dispute reported | 06/30/2026 | 1228715677 |
| Principal investigator 1 | PFIZER INC. | $96.00 | 11/06/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE | No dispute reported | 06/30/2026 | 1228718399 |
| Principal investigator 1 | ABBVIE INC. | $59,703.04 | 11/05/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202522503 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647275 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647277 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647279 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647281 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647283 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647285 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647287 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647475 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647477 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.75 | 11/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220647491 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 11/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220647493 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220647495 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 11/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220647497 |
| Principal investigator 1 | Genentech, Inc. | $5,553.00 | 10/29/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211590517 |
| Principal investigator 1 | Novo Nordisk AS | $823.32 | 10/29/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4801 | No dispute reported | 06/30/2026 | 1213704113 |
| Principal investigator 1 | Novo Nordisk AS | $748.69 | 10/29/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4352 | No dispute reported | 06/30/2026 | 1213755235 |
| Principal investigator 1 | Novo Nordisk AS | $250.00 | 10/29/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4801 | No dispute reported | 06/30/2026 | 1213756218 |
| Principal investigator 1 | Novo Nordisk AS | $1,800.00 | 10/29/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4801 | No dispute reported | 06/30/2026 | 1213756904 |
| Principal investigator 1 | Novo Nordisk AS | $2,250.00 | 10/29/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4801 | No dispute reported | 06/30/2026 | 1213845137 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,267.44 | 10/29/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184253704 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 10/27/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220647501 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 10/27/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220647503 |
| Principal investigator 1 | Genentech, Inc. | $746.00 | 10/23/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590528 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $391.52 | 10/16/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220793669 |
| Principal investigator 1 | Genentech, Inc. | $1,206.00 | 10/16/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590521 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $6,538.00 | 10/16/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211590596 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,154.00 | 10/16/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211590600 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $8,456.00 | 10/16/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211590605 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $26,213.00 | 10/16/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211590609 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,500.00 | 10/16/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211590613 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $646.00 | 10/16/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211590617 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $15,852.33 | 10/16/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184250601 |
| Principal investigator 1 | Eli Lilly and Company | $638.16 | 10/14/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187878075 |
| Principal investigator 1 | Genentech, Inc. | $11,470.00 | 10/09/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211590524 |
| Principal investigator 1 | Genentech, Inc. | $2,238.00 | 10/09/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590536 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,687.45 | 10/09/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184248960 |
| Principal investigator 1 | Genentech, Inc. | $2,627.00 | 10/03/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590533 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,440.95 | 10/03/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244641 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,885.13 | 10/03/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184244643 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647261 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647263 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647265 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647267 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647269 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647271 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647273 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647471 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647473 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $116.60 | 09/24/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647251 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $179.82 | 09/24/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647253 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $803.00 | 09/24/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647255 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $22.62 | 09/24/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647257 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20.70 | 09/24/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647259 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 09/24/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647463 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $365.00 | 09/24/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647465 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.22 | 09/24/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647467 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.28 | 09/24/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647469 |
| Principal investigator 1 | Eli Lilly and Company | $575.75 | 09/24/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187878073 |
| Principal investigator 1 | Eli Lilly and Company | $304.00 | 09/24/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187878741 |
| Principal investigator 1 | Novo Nordisk AS | $2,858.89 | 09/19/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN8640-4467 | No dispute reported | 06/30/2026 | 1213777013 |
| Principal investigator 1 | ABBVIE INC. | $5,333.04 | 09/17/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202511186 |
| Principal investigator 1 | Novo Nordisk AS | $1,000.00 | 09/17/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4801 | No dispute reported | 06/30/2026 | 1213721775 |
| Principal investigator 1 | Novo Nordisk AS | $500.00 | 09/17/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4801 | No dispute reported | 06/30/2026 | 1213739013 |
| Principal investigator 1 | Novo Nordisk AS | $3,000.00 | 09/17/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4801 | No dispute reported | 06/30/2026 | 1213796789 |
| Principal investigator 1 | Genentech, Inc. | $16,590.00 | 09/12/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211590484 |
| Principal investigator 1 | Genentech, Inc. | $746.00 | 09/12/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590486 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 09/11/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220793665 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 09/11/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220793667 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,791.48 | 09/10/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184235855 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,474.26 | 09/03/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184235001 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647201 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647203 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647205 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647207 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647209 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647211 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647239 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647433 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647435 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 08/26/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647457 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.44 | 08/26/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647459 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.42 | 08/26/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647461 |
| Principal investigator 1 | Genentech, Inc. | $3,639.00 | 08/26/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590501 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,770.26 | 08/26/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184230351 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,868.48 | 08/21/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220819039 |
| Principal investigator 1 | Genentech, Inc. | $2,431.00 | 08/21/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211590496 |
| Principal investigator 1 | Genentech, Inc. | $9,724.00 | 08/21/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211590505 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,580.21 | 08/21/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184229747 |
| Principal investigator 1 | Genentech, Inc. | $746.00 | 08/14/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590489 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,362.55 | 08/14/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184228313 |
| Principal investigator 1 | Genentech, Inc. | $36,880.00 | 08/07/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211590479 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,695.08 | 08/07/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184226139 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,740.41 | 08/07/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184226141 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647237 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647429 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647431 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.30 | 07/28/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647241 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 07/28/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647243 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 07/28/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647245 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.70 | 07/28/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647247 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20.70 | 07/28/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647249 |
| Principal investigator 1 | Genentech, Inc. | $2,826.00 | 07/22/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590508 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,229.96 | 07/22/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184217769 |
| Principal investigator 1 | Novo Nordisk AS | $2,302.50 | 07/21/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4801 | No dispute reported | 06/30/2026 | 1213745550 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,666.35 | 07/17/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184217070 |
| Principal investigator 1 | Genentech, Inc. | $8,035.00 | 07/10/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211590493 |
| Principal investigator 1 | Genentech, Inc. | $746.00 | 07/10/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590512 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,093.99 | 07/10/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184214366 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,744.86 | 07/10/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184214368 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $853.20 | 07/09/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220819037 |
| Principal investigator 1 | ABBVIE INC. | $9,437.44 | 07/02/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202495565 |
| Principal investigator 1 | PFIZER INC. | $1,150.50 | 07/02/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228762958 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $123.15 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647213 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647215 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647217 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647219 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647221 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647223 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647225 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647227 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647229 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647231 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647233 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647235 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647437 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647439 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647441 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647443 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647445 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647447 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647449 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647451 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647453 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647455 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $21,800.82 | 06/27/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH, LLC | A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus | No dispute reported | 06/30/2026 | 1185552057 |
| Principal investigator 1 | PFIZER INC. | $32,143.43 | 06/26/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228775695 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,893.40 | 06/25/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220819035 |
| Principal investigator 1 | Novo Nordisk AS | $798.19 | 06/25/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4352 | No dispute reported | 06/30/2026 | 1213721760 |
| Principal investigator 1 | Novo Nordisk AS | $2,818.53 | 06/25/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN8640-4467 | No dispute reported | 06/30/2026 | 1213820812 |
| Principal investigator 1 | Novo Nordisk AS | $949.22 | 06/25/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4352 | No dispute reported | 06/30/2026 | 1213842965 |
| Principal investigator 1 | Eli Lilly and Company | $245,007.00 | 06/24/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 | No dispute reported | 06/30/2026 | 1187880375 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,111.00 | 06/24/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590468 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $4,183.00 | 06/24/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590475 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $855.28 | 06/24/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184210644 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,494.00 | 06/24/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184210646 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $855.28 | 06/24/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184210648 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,375.00 | 06/12/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220819023 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $8,995.00 | 06/05/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590459 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,000.00 | 06/05/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590463 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,000.00 | 06/05/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211590472 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,332.70 | 06/05/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184204179 |
| Principal investigator 1 | ABBVIE INC. | $15,069.44 | 06/03/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202487703 |
| Principal investigator 1 | Amgen Inc. | $36,153.46 | 06/02/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH, LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246640509 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647179 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647181 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647183 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647185 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647187 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647189 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647191 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647193 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647195 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647197 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647199 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647409 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647411 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647413 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647415 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647417 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647419 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647421 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647423 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647425 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647427 |
| Principal investigator 1 | Eli Lilly and Company | $65.00 | 05/30/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | No dispute reported | 06/30/2026 | 1187890092 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,271.89 | 05/28/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184198875 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,649.93 | 05/22/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184197593 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,033.18 | 05/22/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184197595 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,238.71 | 05/22/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184197597 |
| Principal investigator 1 | Eli Lilly and Company | $2,539.01 | 05/21/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | No dispute reported | 06/30/2026 | 1187878511 |
| Principal investigator 1 | Novo Nordisk AS | $1,334.02 | 05/21/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN8640-4515 | No dispute reported | 06/30/2026 | 1213750985 |
| Principal investigator 1 | PFIZER INC. | $4,852.58 | 05/14/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228764397 |
| Principal investigator 1 | Eli Lilly and Company | $93,052.00 | 05/13/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187878505 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $70.00 | 05/12/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220793661 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $70.00 | 05/12/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220793663 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,706.40 | 05/09/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220819033 |
| Principal investigator 1 | ABBVIE INC. | $14,690.56 | 05/07/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202482533 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $87.58 | 05/06/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220793659 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,351.40 | 05/05/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220819021 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647157 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647159 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647161 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647163 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647165 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647167 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647169 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647171 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647173 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647175 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647177 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647389 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647391 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647393 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647395 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647397 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647399 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647401 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647403 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647405 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647407 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,868.30 | 05/01/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220819031 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $19,575.71 | 04/30/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH, LLC | a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure | No dispute reported | 06/30/2026 | 1185552059 |
| Principal investigator 1 | Eli Lilly and Company | $527.00 | 04/30/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | No dispute reported | 06/30/2026 | 1187881410 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,848.73 | 04/28/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184190793 |
| Principal investigator 1 | Eli Lilly Export S.A. Puerto Rico Branch | $7,075.45 | 04/24/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 | No dispute reported | 06/30/2026 | 1187878507 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,387.91 | 04/23/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184189139 |
| Principal investigator 1 | Eli Lilly and Company | $3,050.78 | 04/21/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDITIES IN ADOLESCENTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED TRIAL (SURMOUNT-ADOLESCENTS-2) | No dispute reported | 06/30/2026 | 1187878739 |
| Principal investigator 1 | Eli Lilly and Company | $550.00 | 04/21/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN GLARGINE IN ADULTS WITH TYPE 2 DIABETES ON MULTIPLE DAILY INJECTIONS | No dispute reported | 06/30/2026 | 1187881408 |
| Principal investigator 1 | Novo Nordisk AS | $1,172.54 | 04/21/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4352 | No dispute reported | 06/30/2026 | 1213707697 |
| Principal investigator 1 | Novo Nordisk AS | $487.50 | 04/21/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4352 | No dispute reported | 06/30/2026 | 1213746708 |
| Principal investigator 1 | Novo Nordisk AS | $150.00 | 04/21/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN8640-4467 | No dispute reported | 06/30/2026 | 1213756641 |
| Principal investigator 1 | Novo Nordisk AS | $949.22 | 04/21/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4352 | No dispute reported | 06/30/2026 | 1213759202 |
| Principal investigator 1 | Novo Nordisk AS | $2,750.00 | 04/21/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4352 | No dispute reported | 06/30/2026 | 1213832456 |
| Principal investigator 1 | PFIZER INC. | $10,253.44 | 04/18/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228779755 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,460.82 | 04/15/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184183448 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,373.10 | 04/11/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220819019 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,776.84 | 04/08/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184182066 |
| Principal investigator 1 | Eli Lilly and Company | $41,234.00 | 04/07/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A PARALLEL-GROUP TREATMENT, PHASE 2, DOUBLE-BLIND STUDY OF ONCE-WEEKLY SUBCUTANEOUS LY3457263 COMPARED TO PLACEBO IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS ON A STABLE DOSE OF TIRZEPATIDE OR SEMAGLUTIDE WHO FAILED TO ACHIEVE HBA1C GOAL | No dispute reported | 06/30/2026 | 1187878071 |
| Principal investigator 1 | ABBVIE INC. | $2,611.20 | 04/03/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202471588 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647135 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647137 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647139 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647141 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647143 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647145 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647147 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647149 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647151 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647153 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647155 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647369 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647371 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647373 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647375 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647377 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647379 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647381 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647383 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647385 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647387 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,999.14 | 04/01/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184180900 |
| Principal investigator 1 | Novo Nordisk AS | $372.60 | 03/31/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4801 | No dispute reported | 06/30/2026 | 1213817745 |
| Principal investigator 1 | Eli Lilly and Company | $4,300.00 | 03/28/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY WITH AN OPEN-LABEL EXTENSION ASSESSING THE EFFICACY, SAFETY, AND PHARMACOKINETICS PHARMACODYNAMICS OF TIRZEPATIDE IN PEDIATRIC AND ADOLESCENT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED WITH METFORMIN, OR BASAL INSULIN, OR BOTH | No dispute reported | 06/30/2026 | 1187878815 |
| Principal investigator 1 | Novo Nordisk AS | $1,051.24 | 03/28/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN8640-4467 | No dispute reported | 06/30/2026 | 1213812790 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,770.29 | 03/25/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184178842 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,550.00 | 03/25/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184178844 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,855.00 | 03/25/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184178846 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,422.00 | 03/25/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184178848 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $611.00 | 03/25/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184178850 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,015.10 | 03/24/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220819029 |
| Principal investigator 1 | PFIZER INC. | $10,161.78 | 03/22/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228798047 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,993.45 | 03/19/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184174560 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,916.10 | 03/13/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220819017 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,960.27 | 03/11/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184170874 |
| Principal investigator 1 | ABBVIE INC. | $12,185.60 | 03/07/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202460435 |
| Principal investigator 1 | PFIZER INC. | $96.00 | 03/06/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE | No dispute reported | 06/30/2026 | 1228706831 |
| Principal investigator 1 | PFIZER INC. | $96.00 | 03/06/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE | No dispute reported | 06/30/2026 | 1228771229 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,515.11 | 03/04/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184156736 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647099 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647101 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647103 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647105 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647107 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647109 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647111 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647113 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647115 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647117 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647119 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647349 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647351 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647353 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647355 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647357 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647359 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647361 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647363 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647365 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647367 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 02/25/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647127 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $365.00 | 02/25/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647129 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.70 | 02/25/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647131 |
| Principal investigator 1 | Eli Lilly and Company | $274.50 | 02/25/2025 | Non-covered Recipient Entity COTTON ONEIL MSD OF STORMONT VAIL HEALTHCARE | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187878531 |
| Principal investigator 1 | Eli Lilly and Company | $45,354.00 | 02/25/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187880369 |
| Principal investigator 1 | Eli Lilly and Company | $2,584.00 | 02/25/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187890338 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,689.55 | 02/25/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184155406 |
| Principal investigator 1 | Novo Nordisk AS | $1,837.98 | 02/21/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4352 | No dispute reported | 06/30/2026 | 1213734522 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,748.30 | 02/20/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220819015 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,894.21 | 02/18/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154222 |
| Principal investigator 1 | PFIZER INC. | $8,120.13 | 02/14/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228771168 |
| Principal investigator 1 | PFIZER INC. | $169.00 | 02/13/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE | No dispute reported | 06/30/2026 | 1228771293 |
| Principal investigator 1 | Novo Nordisk AS | $1,500.00 | 02/07/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4984 | No dispute reported | 06/30/2026 | 1213819687 |
| Principal investigator 1 | ABBVIE INC. | $7,165.44 | 02/06/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202449265 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,347.20 | 02/05/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184152462 |
| Principal investigator 1 | Eli Lilly and Company | $138,997.00 | 02/04/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | No dispute reported | 06/30/2026 | 1187878509 |
| Principal investigator 1 | Eli Lilly and Company | $411.75 | 02/03/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | No dispute reported | 06/30/2026 | 1187880495 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647077 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647079 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647081 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647083 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647085 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647087 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647089 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647091 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647093 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647095 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647097 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647329 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647331 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647333 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647335 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647337 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647339 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647341 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647343 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647345 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647347 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,095.00 | 02/01/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220819013 |
| Principal investigator 1 | Eli Lilly Export S.A. Puerto Rico Branch | $465.00 | 01/31/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A STUDY OF ORFORGLIPRON (LY3502970) IN PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH INSULIN GLARGINE, WITH OR WITHOUT METFORMIN AND/?OR SGLT-2 INHIBITOR (ACHIEVE-5) | No dispute reported | 06/30/2026 | 1187878747 |
| Principal investigator 1 | Eli Lilly and Company | $426.88 | 01/31/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187878503 |
| Principal investigator 1 | Eli Lilly and Company | $626.42 | 01/31/2025 | Non-covered Recipient Entity COTTON ONEIL MSD OF STORMONT VAIL HEALTHCARE | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | No dispute reported | 06/30/2026 | 1187878535 |
| Principal investigator 1 | Eli Lilly and Company | $1,018.63 | 01/31/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) | No dispute reported | 06/30/2026 | 1187878821 |
| Principal investigator 1 | Eli Lilly and Company | $1,394.16 | 01/31/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) | No dispute reported | 06/30/2026 | 1187880045 |
| Principal investigator 1 | Novo Nordisk AS | $1,433.70 | 01/31/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4801 | No dispute reported | 06/30/2026 | 1213706833 |
| Principal investigator 1 | Novo Nordisk AS | $1,000.00 | 01/31/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN8640-4467 | No dispute reported | 06/30/2026 | 1213743931 |
| Principal investigator 1 | Novo Nordisk AS | $3,780.00 | 01/31/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN8640-4467 | No dispute reported | 06/30/2026 | 1213784510 |
| Principal investigator 1 | Novo Nordisk AS | $374.35 | 01/31/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH | NN9535-4352 | No dispute reported | 06/30/2026 | 1213830855 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $195,819.40 | 01/29/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH, LLC | A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 in Participants Living with Obesity or Overweight with Comorbidity | No dispute reported | 06/30/2026 | 1185552061 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,856.51 | 01/29/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184149890 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 01/27/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647121 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.70 | 01/27/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647123 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16.56 | 01/27/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647125 |
| Principal investigator 1 | Eli Lilly and Company | $1,287.98 | 01/27/2025 | Non-covered Recipient Entity COTTON ONEIL MSD OF STORMONT VAIL HEALTHCARE | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDITIES IN ADOLESCENTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED TRIAL (SURMOUNT-ADOLESCENTS-2) | No dispute reported | 06/30/2026 | 1187878447 |
| Principal investigator 1 | Eli Lilly and Company | $4,464.18 | 01/27/2025 | Non-covered Recipient Entity STUDYMETRIX RESEARCH LLC | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | No dispute reported | 06/30/2026 | 1187893356 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,840.46 | 01/27/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190310939 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,638.00 | 01/22/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220819011 |
| Principal investigator 1 | Eli Lilly and Company | $33,587.00 | 01/21/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A STUDY OF ORFORGLIPRON (LY3502970) IN PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH INSULIN GLARGINE, WITH OR WITHOUT METFORMIN AND/?OR SGLT-2 INHIBITOR (ACHIEVE-5) | No dispute reported | 06/30/2026 | 1187880367 |
| Principal investigator 1 | Eli Lilly and Company | $25,240.00 | 01/21/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187880493 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $7,931.90 | 01/21/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190312463 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,210.24 | 01/21/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184149058 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,574.70 | 01/17/2025 | Non-covered Recipient Entity Consano Clinical Research LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220819027 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,690.71 | 01/17/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184148113 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $99,076.20 | 01/17/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184148115 |
| Principal investigator 1 | Eli Lilly and Company | $8,940.63 | 01/13/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY | No dispute reported | 06/30/2026 | 1187880491 |
| Principal investigator 1 | Eli Lilly and Company | $21,602.59 | 01/09/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187878391 |
| Principal investigator 1 | Eli Lilly and Company | $5,645.31 | 01/09/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1187878823 |
| Principal investigator 1 | Eli Lilly and Company | $824.47 | 01/07/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) | No dispute reported | 06/30/2026 | 1187878813 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,249.97 | 01/07/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184145836 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,379.10 | 01/07/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184145838 |
| Principal investigator 1 | Eli Lilly and Company | $171,510.00 | 01/06/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | No dispute reported | 06/30/2026 | 1187878499 |
| Principal investigator 1 | Eli Lilly and Company | $87,394.00 | 01/06/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) | No dispute reported | 06/30/2026 | 1187878501 |
| Principal investigator 1 | Eli Lilly and Company | $378.37 | 01/06/2025 | Non-covered Recipient Entity COTTON ONEIL MSD OF STORMONT VAIL HEALTHCARE | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | No dispute reported | 06/30/2026 | 1187878767 |
| Principal investigator 1 | Eli Lilly and Company | $30,645.08 | 01/06/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187878817 |
| Principal investigator 1 | Eli Lilly and Company | $162,449.49 | 01/06/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDITIES IN ADOLESCENTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED TRIAL (SURMOUNT-ADOLESCENTS-2) | No dispute reported | 06/30/2026 | 1187878819 |
| Principal investigator 1 | Eli Lilly and Company | $51,532.00 | 01/06/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187879675 |
| Principal investigator 1 | Eli Lilly and Company | $279,288.00 | 01/06/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | No dispute reported | 06/30/2026 | 1187879677 |
| Principal investigator 1 | Eli Lilly and Company | $91,123.00 | 01/06/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) | No dispute reported | 06/30/2026 | 1187879679 |
| Principal investigator 1 | Eli Lilly and Company | $19,101.00 | 01/06/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1187880253 |
| Principal investigator 1 | Eli Lilly and Company | $100,659.00 | 01/06/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | No dispute reported | 06/30/2026 | 1187880371 |
| Principal investigator 1 | Eli Lilly and Company | $61,576.00 | 01/06/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) | No dispute reported | 06/30/2026 | 1187880373 |
| Principal investigator 1 | Eli Lilly and Company | $716,134.00 | 01/06/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY | No dispute reported | 06/30/2026 | 1187881406 |
| Principal investigator 1 | Eli Lilly and Company | $83,573.00 | 01/06/2025 | Non-covered Recipient Entity CONSANO CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187882644 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647057 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647059 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647061 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647063 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647065 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647067 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647069 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647071 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647073 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647075 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220647133 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647309 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647311 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647313 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647315 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647317 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647319 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647321 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647323 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647325 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Consano Clinical Research | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220647327 |